trending Market Intelligence /marketintelligence/en/news-insights/trending/MeukBUTsAUAgylygNxtd4A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lonza Group's full-year 2019 profit up 12.8% YOY

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Lonza Group's full-year 2019 profit up 12.8% YOY

Lonza Group Ltd. said its full-year 2019 core profit rose 12.8% year over year driven by the Swiss company's pharma-related businesses.

The Basel, Switzerland-based company posted full-year 2019 core profit of CHF1.01 billion, or CHF13.59 per share, up from CHF899 million, or CHF11.98 per share, a year earlier.

The S&P Global Market Intelligence consensus normalized EPS estimate for 2019 was CHF12.96.

Lonza Group's 2019 sales amounted to CHF5.92 billion, a 6.8% yearly increase from CHF5.54 billion. The company's pharma biotech and nutrition segment booked full-year sales of CHF4.17 billion, up 11% from CHF3.76 billion in the year-ago period.

For 2020, Lonza expects above mid-single-digit sales growth, with high single-digit sales growth for its pharma biotech and nutrition segment and low single-digit sales growth for its specialty ingredients business.

Lonza Group continues to forecast CHF7.1 billion in sales and core EBITDA margin of 30.5% as part of its mid-term guidance for 2022.

Meanwhile, the company named Christoph Mäder as lead independent director in November 2019, while the search for a new CEO continues.